148 related articles for article (PubMed ID: 30702869)
21. Cell-specific aptamers and their conjugation with nanomaterials for targeted drug delivery.
Liao J; Liu B; Liu J; Zhang J; Chen K; Liu H
Expert Opin Drug Deliv; 2015 Mar; 12(3):493-506. PubMed ID: 25430795
[TBL] [Abstract][Full Text] [Related]
22. Synthesis and Characterization of Aptamer-Targeted SNALPs for the Delivery of siRNA.
Wilner SE; Levy M
Methods Mol Biol; 2016; 1380():211-24. PubMed ID: 26552829
[TBL] [Abstract][Full Text] [Related]
23. A Dual Targeting Dendrimer-Mediated siRNA Delivery System for Effective Gene Silencing in Cancer Therapy.
Dong Y; Yu T; Ding L; Laurini E; Huang Y; Zhang M; Weng Y; Lin S; Chen P; Marson D; Jiang Y; Giorgio S; Pricl S; Liu X; Rocchi P; Peng L
J Am Chem Soc; 2018 Nov; 140(47):16264-16274. PubMed ID: 30346764
[TBL] [Abstract][Full Text] [Related]
24. What potential do aptamers hold in therapeutic delivery?
Shigdar S
Ther Deliv; 2017 Feb; 8(2):53-55. PubMed ID: 28088878
[No Abstract] [Full Text] [Related]
25. Recent advances in siRNA delivery.
Sarisozen C; Salzano G; Torchilin VP
Biomol Concepts; 2015 Dec; 6(5-6):321-41. PubMed ID: 26609865
[TBL] [Abstract][Full Text] [Related]
26. Self-assembling peptide-based nanoparticles for siRNA delivery in primary cell lines.
Deshayes S; Konate K; Rydström A; Crombez L; Godefroy C; Milhiet PE; Thomas A; Brasseur R; Aldrian G; Heitz F; Muñoz-Morris MA; Devoisselle JM; Divita G
Small; 2012 Jul; 8(14):2184-8. PubMed ID: 22514050
[No Abstract] [Full Text] [Related]
27. Methods for assembling B-cell lymphoma specific and internalizing aptamer-siRNA nanoparticles via the sticky bridge.
Zhou J; Rossi JJ; Shum KT
Methods Mol Biol; 2015; 1297():169-85. PubMed ID: 25896003
[TBL] [Abstract][Full Text] [Related]
28. Nucleic acid aptamer-mediated drug delivery for targeted cancer therapy.
Zhu H; Li J; Zhang XB; Ye M; Tan W
ChemMedChem; 2015 Jan; 10(1):39-45. PubMed ID: 25277749
[TBL] [Abstract][Full Text] [Related]
29. Rekindling RNAi Therapy: Materials Design Requirements for In Vivo siRNA Delivery.
Kim B; Park JH; Sailor MJ
Adv Mater; 2019 Dec; 31(49):e1903637. PubMed ID: 31566258
[TBL] [Abstract][Full Text] [Related]
30. Molecular-Targeted Immunotherapeutic Strategy for Melanoma via Dual-Targeting Nanoparticles Delivering Small Interfering RNA to Tumor-Associated Macrophages.
Qian Y; Qiao S; Dai Y; Xu G; Dai B; Lu L; Yu X; Luo Q; Zhang Z
ACS Nano; 2017 Sep; 11(9):9536-9549. PubMed ID: 28858473
[TBL] [Abstract][Full Text] [Related]
31. Tumor-targeting multifunctional nanoparticles for siRNA delivery: recent advances in cancer therapy.
Ku SH; Kim K; Choi K; Kim SH; Kwon IC
Adv Healthc Mater; 2014 Aug; 3(8):1182-93. PubMed ID: 24577795
[TBL] [Abstract][Full Text] [Related]
32. Anti-Mucin1 Aptamer-Conjugated Chitosan Nanoparticles for Targeted Co-Delivery of Docetaxel and IGF-1R siRNA to SKBR3 Metastatic Breast Cancer Cells.
Jafari R; Majidi Zolbanin N; Majidi J; Atyabi F; Yousefi M; Jadidi-Niaragh F; Aghebati-Maleki L; Shanehbandi D; Soltani Zangbar MS; Rafatpanah H
Iran Biomed J; 2019 Jan; 23(1):21-33. PubMed ID: 30041514
[TBL] [Abstract][Full Text] [Related]
33. Efficient nanocarriers of siRNA therapeutics for cancer treatment.
Subhan MA; Torchilin VP
Transl Res; 2019 Dec; 214():62-91. PubMed ID: 31369717
[TBL] [Abstract][Full Text] [Related]
34. AIE Featured Inorganic-Organic Core@Shell Nanoparticles for High-Efficiency siRNA Delivery and Real-Time Monitoring.
He X; Yin F; Wang D; Xiong LH; Kwok RTK; Gao PF; Zhao Z; Lam JWY; Yong KT; Li Z; Tang BZ
Nano Lett; 2019 Apr; 19(4):2272-2279. PubMed ID: 30829039
[TBL] [Abstract][Full Text] [Related]
35. Delivery of siRNA Complexed with Palmitoylated α-Peptide/β-Peptoid Cell-Penetrating Peptidomimetics: Membrane Interaction and Structural Characterization of a Lipid-Based Nanocarrier System.
Jing X; Foged C; Martin-Bertelsen B; Yaghmur A; Knapp KM; Malmsten M; Franzyk H; Nielsen HM
Mol Pharm; 2016 Jun; 13(6):1739-49. PubMed ID: 26654841
[TBL] [Abstract][Full Text] [Related]
36. Tumor-homing poly-siRNA/glycol chitosan self-cross-linked nanoparticles for systemic siRNA delivery in cancer treatment.
Lee SJ; Huh MS; Lee SY; Min S; Lee S; Koo H; Chu JU; Lee KE; Jeon H; Choi Y; Choi K; Byun Y; Jeong SY; Park K; Kim K; Kwon IC
Angew Chem Int Ed Engl; 2012 Jul; 51(29):7203-7. PubMed ID: 22696263
[TBL] [Abstract][Full Text] [Related]
37. Peptide-siRNA nanotherapeutics in arthritis.
Pham CT; Pan H; Wickline SA
Oncotarget; 2015 Jun; 6(17):14731-2. PubMed ID: 26142704
[No Abstract] [Full Text] [Related]
38. Systemic delivery of siRNA by aminated poly(α)glutamate for the treatment of solid tumors.
Polyak D; Krivitsky A; Scomparin A; Eliyahu S; Kalinski H; Avkin-Nachum S; Satchi-Fainaro R
J Control Release; 2017 Jul; 257():132-143. PubMed ID: 27356019
[TBL] [Abstract][Full Text] [Related]
39. Development of siRNA-loaded chitosan nanoparticles targeting Galectin-1 for the treatment of glioblastoma multiforme via intranasal administration.
Van Woensel M; Wauthoz N; Rosière R; Mathieu V; Kiss R; Lefranc F; Steelant B; Dilissen E; Van Gool SW; Mathivet T; Gerhardt H; Amighi K; De Vleeschouwer S
J Control Release; 2016 Apr; 227():71-81. PubMed ID: 26902800
[TBL] [Abstract][Full Text] [Related]
40. Aptamer-conjugated DNA icosahedral nanoparticles as a carrier of doxorubicin for cancer therapy.
Chang M; Yang CS; Huang DM
ACS Nano; 2011 Aug; 5(8):6156-63. PubMed ID: 21732610
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
